Lucknow News Flash

Wet AMD Market

The Wet AMD market growth is driven by factors like increase in the prevalence of Wet AMD, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Wet AMD market report also offers comprehensive insights into the Wet AMD market size, share, Wet AMD epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Wet AMD market size growth forward. 

Some of the key highlights from the Wet AMD Market Insights Report:

• Several key pharmaceutical companies, including Regeneron Pharmaceuticals, Novartis, Pfizer, Roche, Chengdu Kanghong Biotech, Kodiak Sciences, Opthea Limited, Alkahest Inc, Graybug Vision, REGENXBIO, PanOptica, Clearside Biomedical, Hemera Biosciences, Ribomic USA Inc, and others, are developing novel products to improve the Wet AMD treatment outlook. 
• The total Wet AMD market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
• As per DelveInsight analysis, the Wet AMD market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Wet AMD Market Landscape

Wet AMD Overview 

Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. The dry (atrophic) type affects approximately 80–90% of individuals with AMD. Its cause is unknown, it tends to progress more slowly than the wet type, and there is no approved treatment or cure. In dry age-related macular degeneration, small white or yellowish deposits, called drusen, form on the retina beneath the macula, causing it to deteriorate or degenerate over time. It accounts for about 80–90% of cases. The complaints of a patient with wet AMD may vary from metamorphopsia, central or paracentral scotoma, to a sudden, nonspecific reduction in central vision. Peripheral vision and color vision are generally unaffected; however, the patient may become legally blind (< 20/200 vision) in the affected eye, particularly if AMD is not treated. Central vision loss can progress over weeks, even days, in a more rapid fashion compared with dry AMD. Patients with advanced late AMD can have geographic atrophy, neovascular AMD, features of both, or disciform scarring, which is the end-stage result of neovascular AMD.

Rapid vision loss, usually over days to weeks, is more typical of wet AMD. Age-related macular degeneration is defined by fundus examination, but the diagnosis of AMD is typically based on age, clinical findings through various tests like Color fundus photography, Fluorescein angiography and/or Optical coherence tomography. Color photography and fluorescein angiography are done when findings suggest wet AMD. The goals of wet AMD treatment are to slow progression, preserve existing vision, and reverse vision loss if possible. Management of Wet AMD is done through anti-VEGF medications, photocoagulation, and /or photodynamic therapy. The choice of other treatments depends on the size, location, and type of neovascularization. Anti-VEGF medications are the most effective and most common treatment for wet AMD. Patients with unilateral wAMD should take the daily nutritional supplements that are recommended for dry AMD to reduce the risk of AMD-induced vision loss in the other eye. Low vision rehabilitation can also be an effective part of a wet AMD treatment plan.

Do you know the treatment paradigms for different countries? Download our Wet AMD Market Sample Report

Recent Breakthrough in the Wet AMD Market:

4DMT completes enrollment of Phase 2 PRISM clinical trial for intravitreal 4D-150 in patients diagnosed with Wet AMD: 4D Molecular Therapeutics this week announced that it has completed enrollment of the Phase 2 Dose Expansion stage of the PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD) over approximately two quarters and that no significant 4D-150 safety events or inflammation have been reported to date.

Wet AMD Epidemiology Segmentation 

DelveInsight’s Wet AMD market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Wet AMD historical patient pools and forecasted Wet AMD patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Wet AMD Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Wet AMD Prevalence 
• Age-Specific Wet AMD Prevalence 
• Gender-Specific Wet AMD Prevalence 
• Diagnosed and Treatable Cases of Wet AMD

Visit for more @ Wet AMD Epidemiological Insights

Wet AMD Treatment Market 

The Wet AMD market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Wet AMD market trends by analyzing the impact of current Wet AMD therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Wet AMD market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Wet AMD market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Wet AMD market in 7MM is expected to witness a major change in the study period 2019-2032.

Wet AMD Emerging Therapy Assessment

Abicipar pegol: Molecular Partners

Abicipar pegol is a long-acting anti-VEGF therapeutic candidate, which was invented by Molecular Partners and initially licensed to Allergan in 2011. The program has been through two positive Phase III studies, CEDAR and SEQUOIA, which supported the non-inferior efficacy of the Abicipar quarterly dosing regimen to maintain vision gains with more than 50 percent fewer injections versus ranibizumab (13 vs. 6) dosed monthly in the first year. In June 2020, a Complete Response Letter was issued for the Biologics License Application for Abicipar pegol, indicating that the rate of intraocular inflammation observed following administration of Abicipar pegol resulted in an unfavorable benefit-risk ratio in the treatment of nAMD (AMD), and that additional work would be required to demonstrate a lower rate of ocular inflammation than what was previously seen in the Phase III studies. In 2021, Molecular Partners regained global rights to Abicipar from AbbVie and is determining appropriate next steps for the program.

SOK583A1: Sandoz

Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea). It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz.

BA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.

BA9101 (LY09004), a biosimilar for Eylea, is a recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection, indicated for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR) in patients with diabetic macular edema, and visual impairment due to pathological myopia secondary to choroidal neovascularization(PM-CNV). As a soluble decoy receptor, LY09004 can bind to cytokines such as VEGF-A, VEGF-B and P1GF, inhibit the downstream signaling pathway of VEGFR, inhibit neovascularization, and reduce vascular permeability, thereby treating pathological neovascularization of the retina and choroid eye diseases.

ADVM-022: Adverum Biotechnologies

ADVM-022 is a recombinant, replication-deficient adeno virus-associated (AAV) gene therapy. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 (AAV.7m8-aflibercept) is administered as a single, in-office intravitreal (IVT) injection, designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance and improve vision outcomes for patients with wet AMD and DME. The therapeutic candidate is in Phase II clinical studies for wet AMD.

Wet AMD Key Companies

• Regeneron Pharmaceuticals
• Novartis
• Pfizer
• Roche
• Chengdu Kanghong Biotech
• Kodiak Sciences
• Opthea Limited
• Alkahest Inc
• Graybug Vision
• REGENXBIO
• PanOptica
• Clearside Biomedical
• Hemera Biosciences
• Ribomic USA Inc

For more information, visit Wet AMD Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Wet AMD Market Report:

• 10 Years Forecast
• 7MM Coverage 
• Descriptive overview of Wet AMD, causes, signs and symptoms, diagnosis, treatment
• Comprehensive insight into Wet AMD epidemiology in the 7MM
• Wet AMD marketed and emerging therapies 
• Wet AMD companies
• Wet AMD market drivers and barriers 

Key Questions Answered in the Wet AMD Market Report 2032:

• What was the Wet AMD market share distribution in 2019, and how would it appear in 2032?
• What is the total Wet AMD market size and the market size by therapy across the 7MM for the study period (2019-32)?
• What are the important findings from 7MM, and which country will have the greatest Wet AMD market size from 2019-32?
• During the study period (2019-2032), at what CAGR is the Wet AMD market projected to expand at 7MM?

Table of Contents:

1 Wet AMD Market Key Comprehensive Insights 

2 Wet AMD Market Report Introduction

3 Competitive Intelligence Analysis for Wet AMD

4 Wet AMD Market Analysis Overview at a Glance

5 Executive Summary of Wet AMD

6 Wet AMD Epidemiology and Market Methodology

7 Wet AMD Epidemiology and Patient Population

8 Wet AMD Patient Journey

9 Wet AMD Treatment Algorithm, Wet AMD Current Treatment, and Medical Practices

10 Key Endpoints in Wet AMD Clinical Trials

11 Wet AMD Marketed Therapies 

12 Wet AMD Emerging Therapies

13 Wet AMD: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Wet AMD

16 Wet AMD Market Key Opinion Leaders Reviews

18 Wet AMD Market Drivers

19 Wet AMD Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Wet AMD Epidemiology 2032

DelveInsight’s “Wet AMD – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Wet AMD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Wet AMD Pipeline 2023

“Wet AMD Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Wet AMD market. A detailed picture of the Wet AMD pipeline landscape is provided, which includes the disease overview and Wet AMD treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/